Pharmacopsychiatry 2018; 51(03): 109-110
DOI: 10.1055/s-0038-1649528
Abstracts
Georg Thieme Verlag KG Stuttgart · New York

Therapeutic Drug Monitoring in children and adolescents – looking 10 years back and forward

K Egberts
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
4   Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V.
,
SY Dang
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
,
P Plener
2   Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Ulm, Ulm, Germany
3   Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
4   Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V.
,
A Karwautz
3   Department of Child and Adolescent Psychiatry, Medical University Vienna, Vienna, Austria
4   Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V.
,
R Taurines
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
4   Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V.
,
M Romanos
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
4   Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V.
,
M Gerlach
1   Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Wuerzburg, Germany
4   Competence Network Therapeutic Drug Monitoring (TDM-KJP) e.V.
› Author Affiliations
Further Information

Publication History

Publication Date:
09 May 2018 (online)

Also available at
 

Clinical guidelines recommend Therapeutic Drug Monitoring (TDM) for children and adolescents treated with psychotropic drugs. However, data for the concentrationeffect relationship of most psychotropic drugs in children and adolescents are scarce in comparison to adult psychiatry. In order to optimize the benefit-harm balance of psychopharmacotherapy by promoting TDM in this field, the German-Swiss-Austrian competence-network 'TDM in Child and Adolescent psychiatry' (www.TDM-KJP.com) was founded 10 years ago. The network, having started with 11 centers, collects demographic, disease, safety and effectiveness data from children and adolescents treated with psychotropic drugs in a standardized and systematic way as well as measures blood concentrations (TDM). Currently, 42 centers and institutions participate and several naturalistic TDM-studies in pediatric patients treated with different antipsychotics (e.g. aripiprazole, olanzapine, tiapride) and antidepressants (e.g. fluoxetine, sertraline, escitalopram) have been conducted. Selected data from these studies as well as first results from an ongoing clinical pharmacovigilance monitoring project on the (off-label) use of antipsychotics and antidepressants in children and adolescents ('TDM-VIGIL'-study, funded by the Federal Institute of Drugs and Medical Devices, BfArM) will be presented underlining the importance of age-specific approaches in prescribing psychotropics and in monitoring children and adolescents. Furthermore, clinical and practical experiences with the acceptance and implementation of TDM in this patient group will be given and, finally, future perspectives will be sketched.